🧬 biology

Fecal Microbiota Transplantation Alleviates Asthmatic Airway Inflammation via the Microbiota–Gut–Lung Axis and Tlrs-IL-33 Signaling

This study demonstrates that fecal microbiota transplantation alleviates asthmatic airway inflammation by modulating the microbiota–gut–lung axis through the TLRs-IL-33 signaling pathway, offering a potential microecological therapeutic strategy for asthma.

Original authors: Yilin Zhang, Liang Ma, Dinghui Qiu, Zeren Jiang, Zhiying Huang, Fei Wang, Wenwei Luo, Shuaili Xu, Liwen Zhang, Yu Wan

Published 2026-06-28

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Yilin Zhang, Liang Ma, Dinghui Qiu, Zeren Jiang, Zhiying Huang, Fei Wang, Wenwei Luo, Shuaili Xu, Liwen Zhang, Yu Wan

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ⚕️ This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer

The Big Picture: The "Gut-Lung" Connection

Imagine your body as a house. Usually, we think of the lungs as the "windows" that let air in and the gut (intestines) as the "kitchen" where food is processed. For a long time, doctors thought these two rooms were totally separate.

This study suggests they are actually connected by a secret tunnel called the "Gut-Lung Axis." The researchers found that if the "kitchen" (your gut bacteria) gets messy, the "windows" (your lungs) can get dirty and inflamed, leading to asthma.

The Problem: A Noisy Alarm System

In people with asthma, the lungs are constantly on high alert.

The Alarm: There is a protein called IL-33 that acts like a smoke alarm. In asthma, this alarm is stuck in the "ON" position, screaming "Fire!" even when there isn't one.
The Reaction: This false alarm wakes up the immune system's "firefighters" (Th2 cells), causing swelling, mucus, and trouble breathing.
The Root Cause: The study found that this alarm gets triggered because the gut bacteria are out of balance (dysbiosis). When the gut is messy, it sends signals that tell the lungs to turn up the volume on that alarm.

The Experiment: Cleaning the Kitchen to Fix the Windows

The scientists used mice to test a specific treatment: Fecal Microbiota Transplantation (FMT).

What is FMT? Think of it as a "garden transplant." Instead of giving the mice medicine to kill the bad weeds, they took healthy soil (stool) from a healthy mouse and planted it into the sick mouse's gut. This was done to see if repopulating the gut with good bacteria could fix the lungs.

They compared four groups of mice:

Healthy mice: No asthma, no treatment.
Sick mice: Had asthma, no treatment.
Sick mice + Standard Medicine: Treated with Budesonide (a common asthma inhaler steroid).
Sick mice + FMT: Treated with the healthy bacteria transplant.
Sick mice + Both: Treated with the medicine and the bacteria transplant.

What Happened? (The Results)

1. The Lungs Calmed Down
The mice that received the healthy bacteria transplant (FMT) had much less inflammation in their lungs. The "windows" were cleaner.

The Analogy: It was like cleaning the dust off the windows. The group that got both the medicine and the bacteria transplant had the cleanest lungs of all, suggesting the two treatments work better together than alone.

2. The Alarm Was Turned Off
The study measured the levels of that "smoke alarm" protein (IL-33).

The Finding: The FMT treatment significantly lowered the levels of IL-33. By fixing the gut bacteria, the signal telling the lungs to panic was silenced.

3. The "Wiring" Was Fixed
The researchers looked at how the bacteria did this. They found a specific pathway in the cells that acts like electrical wiring.

The Pathway: Bad gut bacteria were tripping a switch called TLRs, which turned on the alarm (IL-33).
The Fix: The healthy bacteria from the transplant stopped tripping that switch. They essentially cut the power to the alarm system.

4. The Secret Ingredient: Alpha-Linolenic Acid (ALA)
The scientists wanted to know what in the healthy bacteria was doing the work. They found a specific chemical produced by the good bacteria called Alpha-Linolenic Acid (ALA).

The Discovery: ALA is like a "mute button." When the researchers added ALA directly to lung cells in a petri dish, it stopped the alarm (IL-33) from ringing, even when the cells were being attacked.
The Mechanism: ALA works by blocking the "wiring" (the TLR signaling pathway) that usually tells the lungs to start an inflammatory fire.

5. The Gut Healed Too
Interestingly, the mice with asthma also had damaged guts (like a torn kitchen floor). The FMT treatment didn't just fix the lungs; it also repaired the gut lining, making it strong again. This suggests that fixing the gut is the first step to fixing the lungs.

The Timeline: It Takes Time

The study showed that the treatment didn't work instantly.

Day 14: The mice started getting better.
Day 28: The mice were almost fully recovered.
The Lesson: Just like planting a garden, you can't expect flowers to bloom overnight. The healthy bacteria needed time to settle in, grow, and start producing the helpful chemicals (like ALA) to heal the body.

Summary

This paper claims that asthma isn't just a lung problem; it's a gut problem too.
By transplanting healthy gut bacteria into mice with asthma, the researchers were able to:

Repair the gut lining.
Increase the production of a helpful chemical called ALA.
Use that chemical to silence the "alarm" (IL-33) in the lungs.
Stop the immune system from overreacting, thereby reducing asthma symptoms.

The study concludes that this "Gut-Lung" approach, especially when combined with standard asthma medicine, offers a powerful new way to understand and treat airway inflammation.

Technical Summary: Fecal Microbiota Transplantation Alleviates Asthmatic Airway Inflammation via the Microbiota–Gut–Lung Axis and TLRs-IL-33 Signaling

Problem Statement
Bronchial asthma is a chronic inflammatory airway disease driven by type 2 (Th2) immune dysregulation, characterized by eosinophilic inflammation, mucus overproduction, and airway remodeling. Despite available therapies, many patients remain inadequately controlled. Emerging evidence suggests that gut microbiota (GM) dysbiosis influences pulmonary inflammation via the "gut–lung" axis, potentially through the upregulation of Interleukin-33 (IL-33), an epithelial "alarm hormone" that amplifies Th2 responses. While Fecal Microbiota Transplantation (FMT) has shown promise in restoring intestinal balance, the specific mechanisms by which FMT modulates airway inflammation—particularly regarding the TLRs-IL-33 signaling axis and the role of specific microbial metabolites—remain to be fully elucidated.

Methodology
The study employed a multi-faceted approach combining in vivo animal models, in vitro cell culture, and multi-omics analysis:

Animal Model: Specific pathogen-free (SPF) BALB/c mice were divided into six groups: Control (CTL), Sterile (ABX), Asthma Model (OVA), Budesonide therapy (OVA+Bud), FMT therapy (OVA+FMT), and Combined therapy (OVA+Bud+FMT). Asthma was induced via OVA sensitization and challenge. Mice were treated for 14 and 28 days.
Cell Culture: Mouse alveolar epithelial cells (MLE-12) were used to investigate the direct effects of the gut metabolite $\alpha$ -Linolenic acid (ALA) on IL-33 secretion under Th2 cytokine stimulation (IL-4, IL-5, IL-13).
Interventions:
- FMT: Prepared from fresh fecal suspensions of SPF mice and administered via enema.
- ALA: Administered to MLE-12 cells at varying concentrations (5, 10, 25 $\mu$ M) to test cytotoxicity and anti-inflammatory effects.
Analytical Techniques:
- Histology & Immunohistochemistry (IHC): HE staining for lung and colon inflammation; IHC for TLR2, TLR4, and ZO-1 localization.
- Molecular Biology: RT-qPCR and Western Blotting to quantify mRNA and protein levels of IL-33, sST2, TLRs (2/4), MyD88, IRAK, TRAF6, NF- $\kappa$ B pathway components (p-P65, p-I $\kappa$ B $\alpha$ ), and tight junction protein ZO-1.
- Metabolomics & Sequencing: 16S rRNA sequencing to assess GM diversity and composition; non-targeted metabolomics to identify differential metabolites (specifically ALA).
- Immune Profiling: ELISA to measure cytokine levels (Th1/Th2/Th17) in BALF and serum.

Key Contributions

Mechanistic Elucidation of FMT in Asthma: The study establishes a causal link between GM restoration via FMT and the alleviation of airway inflammation, specifically identifying the suppression of the TLR2/4–MyD88–IRAK–TRAF6–NF- $\kappa$ B signaling axis as a primary mechanism.
Identification of ALA as a Key Mediator: Through metabolomic profiling, the study identifies $\alpha$ -Linolenic acid (ALA) as a critical metabolite enriched by FMT. It demonstrates that ALA directly inhibits IL-33 transcription and translation in airway epithelial cells by blocking TLR-mediated signaling.
Validation of the Gut–Lung Axis: The research provides evidence that FMT not only repairs intestinal barrier function (restoring ZO-1 expression) but also exerts systemic effects on the lungs, supporting the concept that gut integrity is a prerequisite for controlling pulmonary inflammation.
Synergistic Therapeutic Potential: The study documents that combining FMT with standard corticosteroid therapy (Budesonide) yields superior outcomes compared to monotherapy, particularly in restoring immune homeostasis and normalizing lung structure over time.

Results

Alleviation of Airway Inflammation: FMT significantly reduced peribronchial and perivascular inflammatory cell infiltration in lung tissue. The combined therapy (OVA+Bud+FMT) showed the most pronounced effect, nearly restoring normal lung architecture by day 28.
Immune Rebalancing: FMT corrected the OVA-induced Th1/Th2/Th17 imbalance, reducing Th2/Th17 cytokines (IL-4, IL-5, IL-13, IL-17A) and restoring Th1 cytokines (IFN- $\gamma$ ).
Suppression of IL-33/sST2 Axis: FMT treatment significantly decreased IL-33 and sST2 levels in both serum and BALF, indicating a dampening of the epithelial alarm signal.
Inhibition of TLR Signaling: FMT downregulated the expression of TLR2 and TLR4 and their downstream signaling molecules (MyD88, IRAK, TRAF6, p-P65) in lung tissue.
Intestinal Barrier Restoration: FMT reversed OVA-induced colonic injury, reduced the Disease Activity Index (DAI), and restored the expression and membrane localization of the tight junction protein ZO-1.
Microbiota Remodeling: 16S rRNA sequencing revealed that FMT restored GM diversity ( $\alpha$ -diversity) and shifted community composition ( $\beta$ -diversity) toward a control-like state, enriching beneficial taxa (e.g., Bacteroides, Lachnospiraceae) and reducing pathogenic shifts.
Metabolic Reprogramming & ALA Function: Metabolomics identified ALA as a key metabolite restored by FMT. In vitro experiments confirmed that ALA directly inhibits IL-33 expression in MLE-12 cells in a dose-dependent manner without cytotoxicity, specifically by blocking the TLR2/4–NF- $\kappa$ B pathway even in the presence of TLR agonists (LPS/Pam3CSK4).

Significance
The paper claims that these findings provide a theoretical foundation for microecological interventions in asthma. By demonstrating that FMT alleviates airway inflammation through the "gut–lung" axis via the TLRs-IL-33 signaling pathway and the metabolite ALA, the study suggests that targeting the gut microbiome could serve as an effective adjunctive strategy to standard corticosteroid therapy. The observed time-dependent and synergistic effects highlight the potential of FMT to enhance the efficacy of existing treatments and offer new insights into the pathophysiology of allergic airway diseases.